股市必读：华森制药（002907）12月24日主力资金净流出141.66万元

Group 1 - The core point of the article is that Huason Pharmaceutical has received a re-registration approval for its injectable omeprazole sodium, which is a significant product for the company [1][2] - The re-registration approval is valid until January 11, 2031, ensuring the product's continued production and sales [1][2] - The product is included in the national medical insurance and essential drug catalog, and is recommended in multiple clinical guidelines [1] Group 2 - On December 24, the stock price of Huason Pharmaceutical closed at 14.97 yuan, with a slight decrease of 0.13% [1] - The trading volume was 18,600 shares, with a total transaction amount of 27.83 million yuan [1] - The net capital flow showed a net outflow of 141.66 thousand yuan from institutional investors and 125.62 thousand yuan from speculative funds, while retail investors had a net inflow of 267.28 thousand yuan [1][2]